Moderna Cuts R&D by $1.1B, Focus on Key Approvals
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
- Latest
- Trending
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
Boehringer Ingelheim acquires Saiba Animal Health, boosting pet R&D with innovative therapeutic vaccines.
S&P 500 dips 0.9% with tech slump, Moderna drops 6.5% post-vaccine approval, market awaits Fed's Powell.
Biotech firms restructure with layoffs as FDA approves new drugs, exemplifying industry challenges and opportunities.
Sinovac's 2024 revenue drops amidst market challenges, with ongoing vaccine development and international market expansions.
Moderna & Coursera launch a free course on mRNA tech, transforming STEM education and workforce readiness globally.
Fortress Biotech reveals Q2 2024 financials with key FDA updates; NDA and BLA filings signal growth in dermatology and oncology.
Discover how Novo Nordisk, Moderna, and Regeneron are poised for growth amidst market volatility with innovative biotech solutions.
Roivant reports strong clinical progress, with significant Phase 3 study completions, revenue growth, and financial strength.
Novavax reports $415M in Q2 revenue with Sanofi's help, eyeing new vaccine launches and cost reductions.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.